CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

Showing 3 of 3 entries

View as:

Phase: N/A Priority: Normal

NCT ID: NCT03331848 Org: User:

Start: 01/15/18 End: 02/01/19 Due: 02/01/20

Phase: N/A Priority: Normal

NCT ID: NCT02639221 Org: User:

Start: 01/31/16 End: 09/30/16 Due: 09/30/17

Phase: N/A Priority: Normal

NCT ID: NCT03162874 Org: User:

Start: 07/04/17 End: 03/02/20 Due: 03/02/21

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)	NCT03331848	Prexton Therapeutics	user2@example.com	None	2018-01-15	2019-02-01	2020-02-01	-	-	2025-07-14
A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects	NCT02639221	Prexton Therapeutics	user2@example.com	None	2016-01-31	2016-09-30	2017-09-30	-	-	2025-07-14
Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients	NCT03162874	Prexton Therapeutics	user2@example.com	None	2017-07-04	2020-03-02	2021-03-02	-	-	2025-07-14